Sanofi breaks ground on new insulin manufacturing facility in Germany
Panama7/iStock Editorial via Getty Images
- Sanofi (SNY) has broken ground on a new insulin manufacturing facility at its BioCampus in Frankfurt, Germany, with full production of insulin active pharmaceutical ingredients expected to begin in 2032, subject to licensing.
- The facility will be built on a
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.